PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Acute Lymphoblastic Lymphoma. According to GlobalData, Phase I drugs for Acute Lymphoblastic Lymphoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PA-317 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - PA-317 in Acute Lymphoblastic Lymphoma

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PA-317 overview

PA-317 therapy is under development for the treatment of relapsed and refractory CD7 positive acute T-lymphoblastic leukemia and lymphoma, extramedullary NK and T-cell lymphoma, peripheral T-cell lymphoma, vascular immunoblastic T-cell lymphoma, intestinal disease associated T-cell lymphomas, anaplastic large cell lymphoma, T-cell lymphoblastic leukemia, acute lymphocytic leukemia, lymphoblastic lymphoma, relapsed/refractory acute myeloid leukemia and T-cell lymphomas. The therapeutic candidate comprises of autologous, T cells genetically manipulated to express chimeric antigen receptor (CAR) targeting cells expressing CD7 antigen. The therapeutic candidate administered through intravenous route.

PersonGen BioTherapeutics (Suzhou) overview

PersonGen BioTherapeutics (Suzhou) (PersonGen) is a biotechnology company focused on developing CAR-related therapies, analytical antibodies, novel CAR-T therapeutics, and allogeneic cellular therapies. PersonGen is headquartered in Suzhou, Jiangsu, China.

For a complete picture of PA-317’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.